

## Contents

<b>1</b>	<b>Diabetic Complications: Pathobiology of Hyperglycemic Damage and Potential Impact on Treatment</b> .....	1
	M. Brownlee	
	Introduction .....	1
	How does Hyperglycemia Cause Microvascular Damage? .....	1
	Macrovascular Damage: The Role of Free Fatty Acids .....	3
	The Long-Term Influence of Hyperglycemic Memory .....	4
	Potential Therapeutic Approaches: The Role of Transketolase Activation .....	5
	Conclusions .....	6
<b>2</b>	<b>Thiamine and Benfotiamine Therapy for the Prevention of Diabetic Nephropathy</b> .....	9
	P. J. Thornalley, N. Rabbani	
	Introduction .....	9
	Effect of Thiamine and Benfotiamine on Cell Function in Hyperglycemia .....	10
	Prevention of Nephropathy in Experimental Diabetes .....	11
	Can Thiamine Prevent Diabetic Nephropathy in Type 2 Diabetes? .....	14
	Conclusions .....	15
<b>3</b>	<b>Thiamine Deficiency and Renal Function in Diabetes</b> .....	18
	N. Rabbani, P. J. Thornalley	
	Introduction .....	18
	Assessment of Thiamine Sufficiency: The “Thiamine Effect” .....	18
	Thiamine Deficiency in Experimental and Clinical Diabetes .....	18
	The Role of Thiamine Transporters .....	21
	Impaired Renal Re-uptake of Thiamine in Diabetes: The Link to the Hexosamine Pathway .....	21
	Thiamine Status and Renal Function .....	23
	Conclusions .....	24

<b>4</b>	<b>Protective Effects of Thiamine and Benfotiamine on Retinal Endothelial Cells and Pericytes in High-Glucose Conditions: Relevance to Diabetic Retinopathy</b> .....	26
	E. Beltramo	
	Introduction .....	26
	Effects of Thiamine and Benfotiamine in Endothelial Cells .....	27
	Effects of Thiamine and Benfotiamine in Retinal Pericytes .....	28
	Prevention of Increased Apoptosis and AGE Production by Thiamine and Benfotiamine .....	30
	Diabetic Retinopathy: The Impact of the Major Pathways of Glycolysis ...	30
	Establishment of an Immortalized Human Retinal Pericyte Line .....	33
	Conclusions .....	34
<b>5</b>	<b>Diabetic Neuropathy: Clinical Problems and Potential Therapeutic Approaches</b> .....	36
	P. Kempler	
	Introduction .....	36
	Distal Symmetrical Polyneuropathy: Symptoms and Diagnosis .....	36
	Therapy for Diabetic Neuropathy .....	37
	Pathogenetically Oriented Treatment ..	38
	Glycemic Control and Management of Risk Factors .....	38
	Aldose Reductase Inhibitors .....	39
	PKC inhibitors .....	39
	Benfotiamine .....	39
	$\alpha$ -Lipoic Acid .....	41
	Symptomatic Treatment of Diabetic Polyneuropathy .....	42
	Conclusions .....	42
<b>6</b>	<b>Treatment of Diabetic Polyneuropathy with Benfotiamine: Results of the BENDIP Study</b> .	45
	H. Stracke	
	Introduction .....	45
	Characteristics of Benfotiamine .....	46
	The BENDIP Study .....	47
	Design .....	47
	Results .....	49
	Potential and Limitations .....	50
	Conclusions .....	51
<b>7</b>	<b>Prevention of Postprandial Endothelial Dysfunction</b> .....	54
	A. Stirban	
	Introduction .....	54
	Endothelial Dysfunction .....	54
	Advanced Glycation Endproducts .....	55
	Synergism of Exogeneous and Endogeneous AGEs .....	56
	AGEs, Endothelial Dysfunction, and Oxidative Stress in Diabetes .....	56
	Is There a Direct Antioxidative Effect of Benfotiamine? .....	60
	Conclusions .....	62
	<b>Index</b> .....	65